Metabolism and Pharmacokinetics of Allitinib in Cancer Patients: The Roles of Cytochrome P450s and Epoxide Hydrolase in its Biotransformation

Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer

Geyer, C. E., Forster, J. K., Lindquist, D. L., Chan, S. Y. T., Romieu, C. G., Pieńkowski, T., Jagiełło-Gruszfeld, A., Crown, J. P., Chan, A., Kaufman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa064320 · Cited by 3,426 · see citing works

The ErbB signaling network: receptor heterodimerization in development and cancer

Olayioye, M. A., Neve, R. M., Lane, H. A., & Hynes, N. E. (2000) · The EMBO Journal · doi:10.1093/emboj/19.13.3159 · Cited by 2,438 · see citing works

Antitumor Activity of HKI-272, an Orally Active, Irreversible Inhibitor of the HER-2 Tyrosine Kinase

Rabindran, S. K., Discafani, C. M., Rosfjord, E. C., Baxter, M., Floyd, M. B., Golas, J., Hallett, W. A., Johnson, B. D., Nilakantan, R., Overbeek, E., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2868 · Cited by 642 · see citing works

Phase I Safety, Pharmacokinetics, and Clinical Activity Study of Lapatinib (GW572016), a Reversible Dual Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinases, in Heavily Pretreated Patients With Metastatic Carcinomas

Burris, H. A., Hurwitz, H. I., Dees, E. C., Dowlati, A., Blackwell, K., O’Neil, B. H., Marcom, P. K., Ellis, M. J., Overmoyer, B. A., Jones, S. F., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.16.584 · Cited by 619 · see citing works

The Crystal Structure of a Truncated ErbB2 Ectodomain Reveals an Active Conformation, Poised to Interact with Other ErbB Receptors

Garrett, T., McKern, N. M., Lou, M., ELLEMAN, T. C., Adams, T. E., Lovrecz, G. O., Kofler, M., Jorissen, R. N., Nice, E. C., Burgess, A. W., et al. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00048-0 · Cited by 614 · see citing works

Biochemical and Clinical Implications of the ErbB/HER Signaling Network of Growth Factor Receptors

Klapper, L. N., Kirschbaum, M. H., Seta, M., & Yarden, Y. (1999) · Advances in cancer research · doi:10.1016/s0065-230x(08)60784-8 · Cited by 541 · see citing works

Cooperativity in Oxidations Catalyzed by Cytochrome P450 3A4

Ueng, Y., Kuwabara, T., Chun, Y., & Guengerich, F. P. (1997) · Biochemistry · doi:10.1021/bi962359z · Cited by 383 · see citing works

Drug Metabolites in Safety Testing

Baillie, T. A. (2002) · Toxicology and Applied Pharmacology · doi:10.1006/taap.2002.9440 · Cited by 371 · see citing works

Discussion

Rodrigues, A. D. (1999) · Biochemical Pharmacology · doi:10.1016/s0006-2952(98)00268-8 · Cited by 370 · see citing works

Phase I Trial of the Irreversible EGFR and HER2 Kinase Inhibitor BIBW 2992 in Patients With Advanced Solid Tumors

Yap, T. A., Vidal, L., Adam, J., Stephens, P., Spicer, J., Shaw, H., Ang, J., Temple, G., Bell, S., Shahidi, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7278 · Cited by 349 · see citing works

Genetic toxicity of some important epoxides

Ehrenberg, L. G., & Hussain, S. (1981) · Mutation Research/Reviews in Genetic Toxicology · doi:10.1016/0165-1110(81)90034-8 · Cited by 317 · see citing works

What is the Objective of the Mass Balance Study? A Retrospective Analysis of Data in Animal and Human Excretion Studies Employing Radiolabeled Drugs

Roffey, S. J., Obach, R. S., Gedge, J. I., & Smith, D. A. (2007) · Drug Metabolism Reviews · doi:10.1080/03602530600952172 · Cited by 241 · see citing works

Binding Mode of the 4-Anilinoquinazoline Class of Protein Kinase Inhibitor: X-ray Crystallographic Studies of 4-Anilinoquinazolines Bound to Cyclin-Dependent Kinase 2 and p38 Kinase

Shewchuk, L. M., Hassell, A. M., Wisely, B., Rocque, W. J., Holmes, W. D., Veal, J. M., & Kuyper, L. F. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm990401t · Cited by 235 · see citing works

A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours

Eskens, F. A. L. M., Mom, C. H., Planting, A. S. T., Gietema, J. A., Amelsberg, A., Huisman, H., van Doorn, L., Burger, H., Stopfer, P., Verweij, J., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604108 · Cited by 234 · see citing works

Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor

Gonzales, A. J., Hook, K. E., Althaus, I. W., Ellis, P. A., Trachet, E., Delaney, A. M., Harvey, P. J., Ellis, T. A., Amato, D. M., Nelson, J. M., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-2232 · Cited by 226 · see citing works

Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects

Bence, A. K., Anderson, E. B., Halepota, M. A., Doukas, M. A., DeSimone, P. A., Davis, G. A., Smith, D. A., Koch, K. M., Stead, A. G., Mangum, S., et al. (2004) · Investigational New Drugs · doi:10.1023/b:drug.0000047104.45929.ea · Cited by 120 · see citing works

Mechanism-Based Inactivation of Cytochrome P450 3A4 by Lapatinib

Teng, W.-C., Oh, J. W., New, L. S., Wahlin, M. D., Nelson, S. D., Ho, H. K., & Chan, E. C. Y. (2010) · Molecular Pharmacology · doi:10.1124/mol.110.065839 · Cited by 119 · see citing works

Human cytochrome P450 3A (CYP3A) mediated midazolam metabolism

enp, J. M., Hall, S. D., Ring, B. J., Strom, S. C., & Wrighton, S. A. (1998) · Pharmacogenetics · doi:10.1097/00008571-199804000-00007 · Cited by 118 · see citing works

Human Metabolism of Lapatinib, a Dual Kinase Inhibitor: Implications for Hepatotoxicity

Castellino, S., O'Mara, M., Koch, K. M., Borts, D. J., Bowers, G. D., & MacLauchlin, C. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.040949 · Cited by 106 · see citing works

Enhanced Anticancer Effect of the Combination of BIBW2992 and Thymidylate Synthase–Targeted Agents in Non–Small Cell Lung Cancer with the T790M Mutation of Epidermal Growth Factor Receptor

Takezawa, K., Okamoto, I., Tanizaki, J., Kuwata, K., Yamaguchi, H., Fukuoka, M., Nishio, K., & Nakagawa, K. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-1009 · Cited by 78 · see citing works

Metabolic Intermediate Complex Formation of Human Cytochrome P450 3A4 by Lapatinib

Takakusa, H., Wahlin, M. D., Zhao, C., Hanson, K. L., New, L. S., Chan, E. C. Y., & Nelson, S. D. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.037531 · Cited by 59 · see citing works

AST1306, A Novel Irreversible Inhibitor of the Epidermal Growth Factor Receptor 1 and 2, Exhibits Antitumor Activity Both In Vitro and In Vivo

Xie, H., Lin, L., Tong, L., Jiang, Y., Zheng, M., Chen, Z., Jiang, X., Zhang, X., Ren, X., Qu, W., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021487 · Cited by 48 · see citing works

Kinetics of Propylene Oxide Metabolism in Microsomes and Cytosol of Different Organs from Mouse, Rat, and Humans

Faller, T., Csanády, G. A., Kreuzer, P. E., Baur, C. M., & Filser, J. G. (2001) · Toxicology and Applied Pharmacology · doi:10.1006/taap.2001.9135 · Cited by 45 · see citing works

Interaction of Lapatinib with Cytochrome P450 3A5

Chan, E. C. Y., New, L. S., Chua, T. B., Yap, C. W., Ho, H. K., & Nelson, S. D. (2012) · Drug Metabolism and Disposition · doi:10.1124/dmd.112.044958 · Cited by 42 · see citing works

Propylene Oxide in Blood and Soluble Nonprotein Thiols in Nasal Mucosa and Other Tissues of Male Fischer 344/N Rats Exposed to Propylene Oxide Vapors--Relevance of Glutathione Depletion for Propylene Oxide-Induced Rat Nasal Tumors

Lee, M. S. (2004) · Toxicological Sciences · doi:10.1093/toxsci/kfi006 · Cited by 31 · see citing works

Lapatinib-induced hepatitis: A case report

Peroukides, S. (2011) · World Journal of Gastroenterology · doi:10.3748/wjg.v17.i18.2349 · Cited by 28 · see citing works

Quantitative structure-activity relationships for the mutagenicity of propylene oxides with Salmonella

Hooberman, B. H., Chakraborty, P. K., & Sinsheimer, J. E. (1993) · Mutation Research/Genetic Toxicology · doi:10.1016/0165-1218(93)90085-r · Cited by 18 · see citing works

Connecting the Chemical and Biological Reactivity of Epoxides

González‐Pérez, M., Gómez‐Bombarelli, R., Arenas‐Valgañón, J., Pérez‐Prior, M. T., García-Santos, M. P., Calle, E., & Casado, J. (2012) · Chemical Research in Toxicology · doi:10.1021/tx300389z · Cited by 14 · see citing works

Development and validation of a sensitive LC–MS/MS assay for the simultaneous quantification of allitinib and its two metabolites in human plasma

Lin, L., Gao, Z., Chen, X., & Zhong, D. (2013) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2013.07.003 · Cited by 7 · see citing works

Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials

Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396 · see citing works

Covalent binding design strategy: A prospective method for discovery of potent targeted anticancer agents

Wang, L., Zhao, J., Yao, Y., Wang, C., Zhang, J., Shu, X. H., Sun, X., Li, Y., Liu, K., Yuan, H., et al. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.09.024 · Cited by 39 · see citing works

Chemical inhibitors of CYP450 enzymes in liver microsomes: combining selectivity and unbound fractions to guide selection of appropriate concentration in phenotyping assays

Nirogi, R. V. S., Palacharla, V. R. C., Uthukam, V., Manoharan, A., Srikakolapu, S. R., Kalaikadhiban, I., Boggavarapu, R. K., Ponnamaneni, R. K., Ajjala, D. R., & Bhyrapuneni, G. (2014) · Xenobiotica · doi:10.3109/00498254.2014.945196 · Cited by 37 · see citing works

Non-cytochrome P450 enzymes involved in the oxidative metabolism of xenobiotics: Focus on the regulation of gene expression and enzyme activity

Pang, X., Tang, C., Guo, R., & Chen, X. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.108020 · Cited by 26 · see citing works

Plasma pharmacochemistry combined with pharmacokinetics and pattern recognition analysis to screen potentially bioactive components from Daming capsule using ultra high performance liquid chromatography with electrospray ionization quadrupole time‐of‐flight mass spectrometry

An, R., Li, Y., Li, M., Bai, Y., Lu, Y., & Du, Z. (2015) · Journal of Separation Science · doi:10.1002/jssc.201401269 · Cited by 16 · see citing works

Predicting Regioselectivity of Cytosolic Sulfotransferase Metabolism for Drugs

Öeren, M., Kaempf, S. C., Ponting, D. J., Hunt, P. A., & Segall, M. (2023) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.3c00275 · Cited by 10 · see citing works

Interpretation of MS–MS spectra of small-molecule signal transduction inhibitors using accurate-m/z data and m/z-shifts with stable-isotope-labeled analogues and metabolites

Niessen, W. M. A., Rosing, H., & Beijnen, J. H. (2021) · International Journal of Mass Spectrometry · doi:10.1016/j.ijms.2021.116559 · Cited by 5 · see citing works

The prenylated phenolic natural product isoglycycoumarin is a highly selective probe for human cytochrome P450 2A6

Wang, Q., Kuang, Y., He, J., Li, K., Song, W., Jin, H., Qiao, X., & Ye, M. (2017) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2017.08.035 · Cited by 5 · see citing works

Unveiling the role of MGMT and DAPK hypermethylation in response to anti‐EGFR agents: Molecular insights for advancing HNSCC treatment

Arantes, L. M. R. B., Oliveira, R. J. D. S., de Carvalho, A. C., Melendez, M. E., Sorroche, B. P., Teixeira, R. D. J., Tostes, K., Palmero, E. I., Reis, R. M., & Carvalho, A. L. (2023) · Head & Neck · doi:10.1002/hed.27602 · Cited by 2 · see citing works

Estudo in vitro do perfil metabólico do agente antitumoral piplartina frente às enzimas do citocromo P450 e predição de parâmetros farmacocinéticos

Moreira, F. D. L. (2017) · doi:10.11606/t.60.2017.tde-03052017-153134

Quantum Mechanics Modeling of Oxetanes as Epoxide Hydrolase Substrates

Di, L., Tu, M., & Ngo, J. (2022) · Letters in Drug Design & Discovery · doi:10.2174/1570180819666220909104037

BindingDB Entry 50003230: Covalent binding design strategy: A prospective method for discovery of potent targeted anticancer agents.

BindingDB (2020) · UC San Diego · doi:10.7270/q2n87dg5

Metabolism and Pharmacokinetics of Allitinib in Cancer Patients: The Roles of Cytochrome P450s and Epoxide Hydrolase in its Biotransformation s

Lin, L., Xie, C., Gao, Z., Chen, X., & Zhong, D. (2013)

PIII-62Metabolism of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, by human cytochrome P-450 CYP3A4, 3A5, 1A1, and 1A2

Li, J., Zhao, M., & Baker, S. D. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.12.270 · Cited by 2 · see citing works

Metabolism and Pharmacokinetics of Novel Selective Vascular Endothelial Growth Factor Receptor-2 Inhibitor Apatinib in Humans

Ding, J., Chen, X., Gao, Z., Dai, X., Li, L., Xie, C., Jiang, H., Zhang, L., & Zhong, D. (2013) · Drug Metabolism and Disposition · doi:10.1124/dmd.112.050310 · Cited by 108 · see citing works

Cytochrome P450-Mediated Bioactivation of the Epidermal Growth Factor Receptor Inhibitor Erlotinib to a Reactive Electrophile

Li, X., Kamenecka, T. M., & Cameron, M. D. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.030361 · Cited by 79 · see citing works

METABOLISM AND EXCRETION OF ERLOTINIB, A SMALL MOLECULE INHIBITOR OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE, IN HEALTHY MALE VOLUNTEERS

Ling, J., Johnson, K. A., Miao, Z., Rakhit, A. K., Pantze, M. P., Hamilton, M., Lum, B. L., & Prakash, C. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.007765 · Cited by 224 · see citing works